NASDAQ OMX

Abiomed Announces Q2 FY 2016 Revenue of $76.4 Million, Up 47% Over Prior Year

29.10.2015 12:00 | NASDAQ OMX

Del

DANVERS, Mass, 2015-10-29 12:00 CET (GLOBE NEWSWIRE) --

Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today reported second quarter fiscal 2016 revenue of $76.4 million, an increase of 47% compared to revenue of $51.9 million for the same period of fiscal 2015. Second quarter fiscal 2016 GAAP net income was $7.7 million or $0.17 per diluted share, an increase of 103% and 89% respectively, compared to GAAP net income of $3.8 million or $0.09 per diluted share for the prior year period.

Financial and operating highlights during the second quarter of fiscal 2016 include:

  • Fiscal second quarter worldwide Impella® heart pump revenue totaled $71.7 million, an increase of 53% compared to revenue of $46.9 million during the same period of the prior fiscal year.  U.S. revenue grew 59% to $66.7 million from $42.0 million in the prior fiscal year with patient usage up 48%.  
     
  • The installed base for Impella 2.5 grew by an additional 27 hospitals, bringing the installed customer base to 1,000 sites.  As part of Abiomed's continued Impella CP® heart pump launch, 45 new hospitals purchased Impella CP, bringing the total number of Impella CP U.S. sites to 739.  
     
  • The Impella RP® heart pump installed base has a goal of 60 sites for the entire fiscal year. As of the end of the second quarter, the Company is ahead of schedule, with an additional 31 hospitals that made initial purchases of the Impella RP during the quarter, bringing the total number to 54  Impella RP U.S. sites. 
     
  • Gross margin for fiscal second quarter 2016 was 84.1% compared to 81.5% in the second quarter of fiscal 2015.  
     
  • Income from operations for the second quarter of fiscal 2016 was $12.8 million, or 16.8% of revenue, compared to $4.2 million, or 8.0% of revenue in the prior year period.
     
  • The Company generated $19 million in cash, cash equivalents and marketable securities, totaling $175.5 million as of September 30, 2015, compared to $156.4 million at June 30, 2015. The Company continues to have no debt. 
     
  • At its annual Investor Day on August 11, Abiomed outlined its long-term growth strategy and five-year vision for revenues and demonstrated future products in development, which can be accessed via webcast here: http://edge.media-server.com/m/p/ckvn5o7f. The future products, which were also recently displayed at the TCT 2015 conference, included:
    • The Impella ECP™ (Expandable Cardiac Power) heart pump on a complete 9 Fr Impella catheter and pump;
    • The Next Generation Impella CP with an increased flow of 4.5 liters/minute and smart sensor technology;
    • The Impella 5.5, which can be implanted via axillary (without a sternotomy), is designed with a 19 Fr pump on a 9 Fr catheter for months of flow of 5.5 liters per minute and patient ambulation;
    • The longer term Impella BTR™ (Bridge to Recovery) heart pump, which can also be implanted via axillary (without a sternotomy), is designed to provide up to a year of 5.5 plus flow driven by a wearable driver.
       
  • The Company also announced the submission of its U.S Food & Drug Administration (FDA) pre-market approval (PMA) supplements in August. The supplements are requesting approval for the Impella family of heart pumps (Impella 2.5, Impella CP and Impella 5.0/LD). The submissions are requesting approval for a set of indications related to the use of the Impella devices in patients suffering cardiogenic shock following acute myocardial infarction or cardiac surgery. A request for a longer duration of support was also included.
     
  • A key clinical paper titled, “Percutaneous left ventricular assist device for high-risk percutaneous coronary interventions: Real-world versus clinical trial experience,” was published in the American Heart Journal during the second quarter. The paper, authored by Mauricio Cohen et al., analyzed the results of high risk PCI (percutaneous coronary intervention) patients in the U.S. Impella (now cVAD™) Registry and determined that real-world clinical outcomes with the Impella 2.5 appeared to be favorable and consistent compared with the randomized PROTECT II trial.
     
  • Seth Bilazarian, MD, was announced as the new Vice President of Interventional Cardiology Programs at Abiomed on October 8. 
     
  • At the Cardiovascular Research Foundation's (CRF) annual Transcatheter Cardiovascular Therapeutics (TCT) 2015 scientific sessions in October, there were over 25 Impella heart pump presentations, 3 Protected PCI symposia and 5 live Impella heart pump cases.


“We have had an exciting start to fiscal year 2016 with first half revenue growth of 49% and establishment of Protected PCI™ as a new indication. As evidenced by our patient growth and awareness at TCT, Protected PCI has been validated by physicians that treat higher risk patients requiring percutaneous hemodynamic support in the cath lab,” said Michael R. Minogue, Chairman, President and Chief Executive Officer, Abiomed. “We are confident that in the years ahead, Abiomed will deliver strong growth, support new indications and countries, and launch new best in class products. As always, Abiomed is committed to meaningfully impacting the lives of our patients and helping our physicians improve outcomes.”

FISCAL YEAR 2016 OUTLOOK

The Company is increasing its fiscal year 2016 guidance for total revenue to be in the range of $305 million to $315 million, up from $300 million to $310 million, representing an increase in revenue of 32% to 37% from the prior year.

The Company is updating its fiscal year guidance for GAAP operating margin to be in the range of 15% to 17%, from the previous guidance range of 14% to 16%.

CONFERENCE CALL

The Company will release financial results for the second quarter of fiscal 2016. The Company will host a conference call to discuss the results on Thursday, October 29, 2015, at 8:00 a.m. EDT. Michael R. Minogue, Chairman, President and Chief Executive Officer; Michael Tomsicek, Vice President and Chief Financial Officer, will host the conference call.

To listen to the call live, please tune into the webcast via http://investor.abiomed.com or dial (855) 212-2361; the international number is (678) 809-1538.  A replay of this conference call will be available beginning at 11 a.m. EDT October 29, 2015 through 11:59 p.m. EDT on October 31, 2015. The replay phone number is (855) 859-2056; the international number is (404) 537-3406. The replay access code is 55643535.

The ABIOMED logo, ABIOMED, Impella, Impella RP and Impella CP are registered trademarks of Abiomed, Inc. in the U.S.A. and certain foreign countries.  Impella ECP, Impella BTR, Protected PCI, Recovering Hearts. Saving lives and cVAD are trademarks of Abiomed, Inc..

ABOUT ABIOMED 

Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support.  Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit: www.abiomed.com

FORWARD-LOOKING STATEMENTS 

This release includes forward-looking statements.  These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” and other words of similar meaning.  These forward-looking statements address various matters including, the development of Abiomed's existing and new products, the Company's progress toward commercial growth, the Company’s guidance for fiscal 2016 revenue and GAAP operating margins and future opportunities. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement.  Applicable risks and uncertainties include, among others, uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and the risks identified under the heading “Risk Factors” in the Company's Annual Report on Form 10-K for the year ended March 31, 2015 and the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, each filed with the Securities and Exchange Commission, as well as other information the Company files with the SEC.  We caution investors not to place considerable reliance on the forward-looking statements contained in this press release.  You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties.  The forward-looking statements in this press release speak only as of the date of this release and the Company undertakes no obligation to update or revise any of these statements.  Our business is subject to substantial risks and uncertainties, including those referenced above.  Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

 

Abiomed, Inc. and Subsidiaries
Consolidated Balance Sheets
(Unaudited)
(in thousands, except share data)
         
    September 30, 2015   March 31, 2015
         
ASSETS        
Current assets:        
Cash and cash equivalents $   54,421     $   22,401  
Short-term marketable securities     121,087         109,557  
Accounts receivable, net      37,119         31,828  
Inventories      23,032         16,774  
Prepaid expenses and other current assets     4,030         4,479  
Deferred tax assets, net     25,715         35,100  
Total current assets     265,404         220,139  
Long-term marketable securities   —       13,996  
Property and equipment, net     11,420         9,127  
Goodwill       32,676         31,534  
In-process research and development     15,243         14,711  
Long-term deferred tax assets, net     44,240         45,206  
Other assets     4,423         3,654  
Total assets $   373,406     $   338,367  
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:      
Accounts payable $   8,788     $   10,389  
Accrued expenses     18,861         21,894  
Deferred revenue     6,803         7,036  
Total current liabilities     34,452         39,319  
Other long-term liabilities     217         183  
Contingent consideration     6,817         6,510  
Long-term deferred tax liabilities     824         795  
Total liabilities     42,310         46,807  
Commitments and contingencies    
Stockholders' equity:      
Class B Preferred Stock, $.01 par value   —     —
 
Common stock, $.01 par value     424         413  
Authorized - 100,000,000 shares; Issued - 43,756,550 shares at September 30, 2015
  and 42,618,717 shares at March 31, 2015;
       
Outstanding - 42,417,469 shares at September 30, 2015 and 41,335,773
  shares at March 31, 2015
       
Additional paid in capital     489,463         465,046  
Accumulated deficit     (120,628 )       (137,222 )
Treasury stock at cost - 1,339,081 shares at September 30, 2015 and 1,282,944
  shares at March 31, 2015
      (23,157 )       (19,347 )
Accumulated other comprehensive loss     (15,006 )       (17,330 )
Total stockholders' equity     331,096         291,560  
Total liabilities and stockholders' equity $   373,406     $   338,367  

 

 

Abiomed, Inc. and Subsidiaries
Consolidated Statements of Operations
(Unaudited)
(in thousands, except share data)
 
    For the Three Months Ended
September 30,
  For the Six Months Ended 
September 30,
    2015   2014   2015   2014
Revenue:                        
Product revenue $   76,354   $     51,774     $   149,780   $     100,434  
Funded research and development     5         164         11         315  
        76,359         51,938         149,791         100,749  
Costs and expenses:                      
Cost of product revenue    12,144         9,612         23,012         19,301  
Research and development    11,569         8,693         21,779         17,755  
Selling, general and administrative      39,829         29,455         77,152         61,053  
        63,542         47,760         121,943         98,109  
Income from operations     12,817         4,178         27,848         2,640  
Other income (loss):                      
Investment income, net   62         36         125         80  
Other income (loss), net     87         (39 )       140         (28 )
        149         (3 )       265         52  
Income before income taxes   12,966         4,175         28,113         2,692  
Income tax provision     5,231         336         11,519         562  
Net income $   7,735   $     3,839     $   16,594   $     2,130  
                         
Basic net income per share $   0.18   $     0.09     $   0.40   $     0.05  
Basic weighted average shares outstanding   42,228         40,448         41,963         40,256  
                         
Diluted net income per share $   0.17   $     0.09     $   0.37   $     0.05  
Diluted weighted average shares outstanding   44,922         42,239         44,778         42,069  

         For further information please contact:
         
         Ingrid Goldberg,
         Director, Investor Relations
         978-646-1590
         ir@abiomed.com
         
         Aimee Genzler
         Director, Corporate Communications
         978-646-1553
         agenzler@abiomed.com

Om NASDAQ OMX

NASDAQ OMX
NASDAQ OMX
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra NASDAQ OMX

Registrer deg med din epostadresse under for å få de nyeste sakene fra NASDAQ OMX på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra NASDAQ OMX

CallidusCloud Wins Eight Gold Stevies® in the 2017 International Business Awards16.8.2017 14:00Pressemelding

CallidusCloud Lead to Money suite recognized as Best B2B New Product of the Year. LeadRocket voted Best New Product or Service of the Year in the Software - Lead Generation Solution category. DUBLIN, Calif., Aug. 16, 2017 (GLOBE NEWSWIRE) -- Callidus Software Inc. (NASDAQ:CALD), a global leader in cloud-based sales, marketing, learning, and customer experience solutions, announced today that it was named the winner of eight Gold Stevie® awards in the 2017 International Business Awards. "The eight Stevie® awards earned highlight CallidusCloud's momentum, commitment to excellence, passion for innovation and customer orientation," said Leslie Stretch, president and CEO of CallidusCloud. "They also recognize the benefits that the Lead to Money suite, honored as the Best New Product in Business-to-Business, accrues to its customers in terms of enabling faster, bigger, and more profitable sales." CallidusCloud's Go

Ascom Myco and Koutio Médipôle optimize care communications and responsiveness16.8.2017 08:00Pressemelding

Ascom Holding AG / Ascom Myco and Koutio Médipôle optimize care communications and responsiveness . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. Enabled by the Ascom Myco smart device, the new Koutio Médipôle is realizing improved care delivery through seamless information flow from the point of care to anywhere. BAAR, Switzerland, Aug. 16, 2017 (GLOBE NEWSWIRE) -- The new Koutio Médipôle hospital in the New Caledonian capital Nouméa, located in the southwest Pacific Ocean, has optimized patient care communications and responsiveness for the new 645-bed facility by deploying Ascom Myco Wi-Fi devices to support clinician teams and Ascom Myco Wi-Fi/GSM handsets, used across paramedic teams. The Ascom solution is seamlessly aligned with clinical workflow and applications (nurs

VistaJet Harnesses the Power of the American Eclipse to Offer Customers a Rare Viewing Opportunity15.8.2017 18:40Pressemelding

VistaJet invites customers to fly in parallel with an astronomical anomaly NEW YORK, Aug. 15, 2017 (GLOBE NEWSWIRE) -- VistaJet, the first and only global aviation company, will be offering customers the opportunity to experience and chase the American Solar Eclipse, appearing for the first time in 99 years on August 21, 2017. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/c0c41d7d-7ad9-4a46-9d2d-dcc1148b4772 The coast-to-coast National Eclipse and astronomical phenomenon will be visible in the United States from approximately 10:15AM PST, with the sun disappearing behind the moon from the Oregon coast, passing through 14 states to South Carolina.  Without being in this 70-mile strip, Americans will not be able to see the sun eclipsed in totality. With unparalleled experience flying into and out of the hardest to reach destinations, VistaJet is offer

NGX Bio Raises $3 Million to Fund Growth of Its DNA Sequencing Marketplace15.8.2017 17:00Pressemelding

SAN FRANCISCO, Aug. 15, 2017 (GLOBE NEWSWIRE) -- NGX Bio, Inc., (www.NGXbio.com) the premier marketplace for online DNA sequencing services, announced it has closed a $3 million funding round.  The round was led by 180 Degree Capital Corp. (NASDAQ:TURN) and included Third Kind Venture Capital, Lateral Capital, the Band of Angels and the Berkeley Angel Network, as well as other investors. NGX Bio was founded in 2014 to provide streamlined, on-line access to next-generation sequencing services for clients seeking high quality, rapid and cost-effective sequencing of both human and non-human samples globally.  Demand for sequencing services is growing exponentially.  NGX Bio's platform matches the sequencing needs of customers with providers who have available sequencing capacity.  Customers are able to purchase a wide range of sequencing services for their samples using NGX Bio's online ordering tools.  NGX Bio offers these services through numerous and deep relationships with its

Hminers Launch the Most Powerful Cryptocurrency Mining Rigs with Unique Features15.8.2017 15:57Pressemelding

Hminers has just introduced three new mining rigs with extraordinary features. The company already has the unique distinction of delivering the first ever 10nm ASIC mining rig in the cryptocurrency market. MIAMI, Aug. 15, 2017 (GLOBE NEWSWIRE) -- Hminers is delighted to announce the mega launch of three new products that will make cryptocurrency mining easy and efficient like never before. This Miami-based organization is one of the most trusted names in the cryptocurrency market with the distinction of creating the world's first 10 nm ASIC Chip. The company's three new products H2U Miner, H4U Miner, and Rack Equipped with 5 x H4U are now up for sale at www.Hminers.com. As the difficulties in bitcoin mining have kept on increasing over the last few years, Hminers has embraced new principles to create multi algorithm based miners. Each of the three new products from the company is built and designed to operate under multiple algorithms and provide custome

Oxford Immunotec Global PLC Announces Pricing of Underwritten Public Offering of Ordinary Shares15.8.2017 15:02Pressemelding

OXFORD, United Kingdom and MARLBOROUGH, Mass., Aug. 15, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced the pricing of its previously announced underwritten public offering of 2,500,000 ordinary shares pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (the "SEC") on Form S-3. The aggregate gross proceeds to Oxford Immunotec, before deducting the underwriting discounts and commissions and offering expenses, will be $40.125 million. The offering is expected to close on or about August 18, 2017, subject to customary closing conditions. In addition, Oxford Immunotec has granted BTIG, LLC, the sole underwriter of the offering, an option to purchase up to 375,000 additional ordinary shares. Oxford Immunotec intends to use th

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom